Praxis Precision Medicines
PRAX
78 hedge funds and large institutions have $135M invested in Praxis Precision Medicines in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 30 closing their positions.
212% more capital invested
Capital invested by funds: $43.1M → $135M (+$91.5M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
1.1% less ownership
Funds ownership: 6.77% → 5.68% (-1.1%)
9% less funds holding
Funds holding: 86 → 78 (-8)
24% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 25
27% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 30
Top Buyers
Top Sellers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.46M |
| 2 |
BlackRock
New York
|
-$2.33M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.64M |
| 4 |
State Street
Boston,
Massachusetts
|
-$774K |
| 5 |
Goldman Sachs
New York
|
-$620K |
PRAX Hedge Fund Activity: Q2 2023 in Review
78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q2 2023, worth a combined $135M — up 212% from $43.1M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PRAX and 22 opened new positions — a net loss of 8 holders — while 25 trimmed existing stakes and 19 added.
The largest buyer was Point72 Asset Management, adding an estimated $10.7M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $3.46M sold.
- 78 institutional investors held Praxis Precision Medicines (PRAX) as of Q2 2023, down from 86 in Q1 2023.
- Funds reported $135M of Praxis Precision Medicines stock for Q2 2023, up 212% quarter-over-quarter.
- 22 funds opened new Praxis Precision Medicines positions in Q2 2023 and 30 closed out, a net change of -8 holders.
- The largest Praxis Precision Medicines buyer in Q2 2023 was Point72 Asset Management, an estimated $10.7M added.
- The largest Praxis Precision Medicines seller in Q2 2023 was Avidity Partners Management, an estimated $3.46M sold.
Based on aggregated 13F filings for Q2 2023.